Effectiveness of Yangxue Qingnao Granules in Preventing Post Thrombolytic Hemorrhage Transformation in Patients With Acute Cerebral Infarction

Inclusion Criteria: * Age ≥ 50 years old, regardless of gender * After the onset of this disease, the National Institutes of Research Stroke Scale score was 2 ≤ NIHSS ≤ 20 points * Patients who have developed symptoms within 4.5 hours and can receive rt PA intravenous thrombolysis treatment * According to the 2019 Diagnosis Points for Major Cerebrovascular Diseases in China, patients with ischemic stroke were diagnosed as having a good recovery from the first or last onset (mRS score ≤ 1 point before this onset) * Obtain the patient or their legal representative to voluntarily sign an informed consent form approved by the ethics committee. Exclusion Criteria: * Intracranial hemorrhagic diseases seen on cranial imaging: hemorrhagic stroke, epidural hematoma, intracranial hematoma, ventricular hemorrhage, subarachnoid hemorrhage, etc; If it is only oozing blood, the researcher can determine whether it is suitable for enrollment * Severe consciousness disorder: NIHSS scored\>1 point in the 1a consciousness level item * After controlling the patient's blood pressure, the systolic blood pressure remains ≥ 180mmHg or the diastolic blood pressure remains ≥ 100mmHg * Blood glucose\<2.8mmol/L (random blood glucose measurement device can be used) * Patients with severe mental disorders and dementia * Diagnosed with severe active liver diseases, such as acute hepatitis, chronic active hepatitis, cirrhosis, etc; Or ALT or AST\>2.0 x ULN * Diagnosed with severe active kidney disease and renal insufficiency; Or serum creatinine\>1.5 × ULN * Concurrent malignant tumors or ongoing anti-tumor treatment; For subjects diagnosed with malignant tumors after enrollment, the decision to continue participating in the study can be based on the researcher's judgment and the subject's willingness * Suffering from severe systemic diseases, with an estimated survival time of\<90 days * History of major surgery within 4 weeks prior to enrollment * Participated in other clinical studies within the first 30 days of randomization, or is currently participating in other clinical studies * The researcher believes that it is not suitable to participate in this clinical study * Patients who are allergic to any ingredient in the study drug